The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia

DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043 · see citing works

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981 · see citing works

Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra

Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · see citing works

Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases

Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445 · see citing works

A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains

Connor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., & LeWitt, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020717.x · Cited by 317 · cited 1× · see citing works

Excitotoxicity and nitric oxide in parkinson's disease pathogenesis

Beal, M. F. (1998) · Annals of Neurology · doi:10.1002/ana.410440716 · Cited by 283 · see citing works

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156 · see citing works

The role of iron in brain ageing and neurodegenerative disorders

Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819 · see citing works

Metals and neuroscience

Bush, A. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00073-3 · Cited by 731 · see citing works

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659 · see citing works

Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo

Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620 · see citing works

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554 · see citing works

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361 · see citing works

Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-κB) activation and cell death by tea extracts in neuronal cultures11Abbreviations: BT, Black Tea; EMSA, Electromobility Shift Assay; EGCG, (-)-Epigallocatechin-3-gallate; GT, Green Tea; NB SH-SY5Y cells, Human neuroblastoma SH-SY5Y cells; 6-OHDA, 6-hydroxydopamine; IL, Interleukin; LDH, Lactate Dehydrogenase; MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-κB, nuclear factor-κB; OS, Oxidative Stress; PD, Parkinson’s Disease; ROS, Reactive Oxygen Species; SNPC, Substantia Nigra Pars Compacta; TBARS, thiobarbituric acid reactive substances.

Levites, Y., Youdim, M. B. H., Maor, G., & Mandel, S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00813-9 · Cited by 291 · see citing works

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246 · see citing works

Iron and neurodegenerative disorders

Thompson, K. J., Shoham, S., & Connor, J. R. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00510-x · Cited by 235 · see citing works

Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28

YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233 · see citing works

Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation

Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A., Lombes, A., Quinn, N., Wills, A., Fletcher, N., Mottershead, J. P., et al. (2006) · Brain · doi:10.1093/brain/awl319 · Cited by 205 · see citing works

The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation

D’Alessio, F., Hentze, M. W., & Muckenthaler, M. U. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.015 · Cited by 200 · see citing works

Decreased transferrin receptor expression by Neuromelanin cells in restless legs syndrome

Connor, J. R., Wang, X. S., Patton, S. M., Menzies, S. L., Troncoso, J. C., Earley, C. J., & Allen, R. P. (2004) · Neurology · doi:10.1212/01.wnl.0000123251.60485.ac · Cited by 199 · see citing works

Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.<i>In vivo</i>selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185 · see citing works

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson?s disease and other neurodegenerative diseases

Youdim, M. B. H., Fridkin, M., & Zheng, H. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0143-x · Cited by 123 · see citing works

Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases

Whitnall, M., & Richardson, D. R. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.008 · Cited by 113 · see citing works

Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration

Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., & Le, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.150 · Cited by 87 · see citing works

Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity

Hare, D. J., Adlard, P. A., Doble, P. A., & Finkelstein, D. I. (2013) · Metallomics · doi:10.1039/c2mt20164j · Cited by 78 · see citing works

Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys

Cass, W. A., Grondin, R., Andersen, A. H., Zhang, Z., Hardy, P. A., Hussey-Andersen, L. K., Rayens, W. S., Gerhardt, G. A., & Gash, D. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.010 · Cited by 67 · see citing works

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease

Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_68 · Cited by 58 · see citing works

Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons

Zheng, H., Youdim, M. B. H., Weiner, L. M., & Fridkin, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.003 · Cited by 53 · see citing works

Toxic Concentrations of Glutamate Induce Ferroptosis without Affecting Mitochondrial Respiration in Rodent Brain Slice Cultures

Vaglio-Garro, A., Theuermann, M., Sweis, K. E., Zavadskis, S., Kokas, M., Környei, Z., Karas, M., Tretter, L., Komlódi, T., Weidinger, A., et al. (2026) · eneuro · doi:10.1523/eneuro.0439-25.2026